/BRRGF
BRRGF Stock - BerGenBio ASA
Healthcare|BiotechnologyOTC
$0.97+0.00%
+$0.00 (+0.00%) • Dec 19
46
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.58
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.07
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BRRGF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.96 – $0.98
TARGET (TP)$1.12
STOP LOSS$0.89
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.56
52W High$2.50
52W Low$0.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $848,000 | $354,000 | $389,000 | $774,000 | $601,000 |
| Gross Profit | $848,000 | $354,000 | $389,000 | $774,000 | $-88,868,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -14786.7% |
| Operating Income | $-151,234,000 | $-191,819,000 | $-305,635,000 | $-314,464,000 | $-261,091,000 |
| Net Income | $-139,282,000 | $-190,401,000 | $-298,609,000 | $-309,417,000 | $-257,061,000 |
| Net Margin | -16424.8% | -53785.6% | -76763.2% | -39976.4% | -42772.2% |
| EPS | $-11.65 | $-19.95 | $-38.65 | $-40.36 | $-39.37 |
Company Overview
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BRRGFBeat Rate
23%
Last 13 quarters
Avg Surprise
-1030.3%
EPS vs Estimate
Beats / Misses
3/10
Last 12 quarters
Latest EPS
$-2.39
Q1 2025
EPS Surprise History
Q1 23
No data
Q2 23
No data
Q3 23
-1591.2%
$-3.16vs$-0.19
Q1 24
-3054.9%
$-3.10vs$-0.10
Q2 24
-1353.8%
$-2.69vs$-0.18
Q3 24
-3455.1%
$-4.16vs$-0.12
Q4 24
-1538.6%
$-2.08vs$-0.13
Q1 25
-2401.5%
$-2.39vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 19, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | — | — | — | — |
Q4 2025 | Nov 19, 2025 | — | — | — | — |
Q3 2025 | Aug 20, 2025 | — | — | — | — |
Q2 2025 | May 21, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | $-0.10 | $-2.39 | -2401.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.13 | $-2.08 | -1538.6% | ✗ MISS |
Q3 2024 | Aug 21, 2024 | $-0.12 | $-4.16 | -3455.1% | ✗ MISS |
Q2 2024 | May 29, 2024 | $-0.18 | $-2.69 | -1353.8% | ✗ MISS |
Q1 2024 | Feb 14, 2024 | $-0.10 | $-3.10 | -3054.9% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.19 | $-3.16 | -1591.2% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | — | $-5.90 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-9.26 | — | — |
Q1 2023 | Feb 16, 2023 | $-0.85 | $-0.87 | -2.4% | ✗ MISS |
Q4 2022 | Nov 15, 2022 | $-0.82 | $-0.67 | +18.3% | ✓ BEAT |
Q3 2022 | Aug 23, 2022 | $-0.83 | $-0.95 | -14.5% | ✗ MISS |
Q2 2022 | May 24, 2022 | $-0.78 | $-0.92 | -17.9% | ✗ MISS |
Q1 2022 | Feb 16, 2022 | $-0.81 | $-0.78 | +3.7% | ✓ BEAT |
Q4 2021 | Nov 16, 2021 | $-1.03 | $-0.80 | +22.3% | ✓ BEAT |
Q3 2021 | Aug 17, 2021 | $-0.94 | $-1.02 | -8.5% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about BRRGF
What is BRRGF's current stock price?
BerGenBio ASA (BRRGF) is currently trading at $0.97 per share. The stock has moved +0.00% today.
What is the analyst price target for BRRGF?
No analyst price targets are currently available for this stock.
What sector is BerGenBio ASA in?
BerGenBio ASA operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is BRRGF's market cap?
BerGenBio ASA has a market capitalization of $0.09 billion, making it a small-cap company.
Does BRRGF pay dividends?
No, BerGenBio ASA does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorDOGP
Dogecoin Cash, Inc.
$0.02
Mkt Cap: $0.0B
FTHWF
Field Trip Health & Wellness Ltd.
$0.04
Mkt Cap: $0.0B
GHSI
Guardion Health Sciences, Inc.
$3.25
Mkt Cap: $0.0B
IPCIF
Intellipharmaceutics International Inc.
$0.15
Mkt Cap: $0.0B
IVITF
Invictus MD Strategies Corp.
$0.00
Mkt Cap: $0.0B
OCTHF
Oxford Cannabinoid Technologies Holdings Plc
$0.00
Mkt Cap: $0.0B
PSCBF
Pascal Biosciences Inc.
$0.11
Mkt Cap: $0.0B
PXMVF
Pixium Vision S.A.
$1.50
Mkt Cap: $0.0B
SEPSF
Asep Medical Holdings Inc
$0.01
Mkt Cap: $0.0B
TRYPF
Tryp Therapeutics Inc.
$0.06
Mkt Cap: $0.0B
Explore stocks similar to BRRGF for comparison